Profit improvement in the dispensing pharmacy business driven by an increase in prescriptions and fees for dispensing services
First written in FY2018-Q3. 8 of 31 entries say "Advanced", first in FY2018. Latest entry: 2026-09-17.
No other company in this theme has enough history to compare yet.
- 2026-09-17WorsenedFinancial results
「As a result, revenue in the dispensing pharmacy business during the first quarter of the current consolidated fiscal year was ¥14,474 million, up 2.3% year on year, while segment profit was ¥158 million, down 32.6%.」
The dispensing pharmacy business increased revenue, but segment profit fell 32.6% year on year, weakening from the recent trend of improving profitability. - FY2026AdvancedAnnual report
「As a result, for the fiscal year, the dispensing pharmacy business recorded revenue of ¥59,331 million, up 12.7% year on year, and segment profit of ¥1,386 million, up 139.8% year on year.」
The dispensing pharmacy business achieved higher revenue and substantially higher profit due to M&A and new store openings, higher prescription volumes, stronger collection of dispensing service fees and improved operating efficiency. - FY2026-H1Higher revenue and improved profit in the dispensing pharmacy businessAnnual report
「During the interim consolidated accounting period, the dispensing pharmacy business recorded revenue of ¥28,479 million, up 14.2% year on year, and segment profit of ¥589 million, up 190.5% year on year.」
The dispensing pharmacy business achieved higher revenue and substantially higher profit due to M&A and new store openings, including the Kanichi Shoten Group, increased profit at stores newly brought into the group, and higher dispensing service fees, including regional healthcare support add-on fees. - FY2025Higher revenue and a sharp decline in profit in the dispensing pharmacy businessAnnual report
「The dispensing pharmacy business recorded revenue of ¥52,625 million, up 19.1% year on year, and segment profit of ¥578 million, down 47.3% year on year.」
Revenue increased due to M&A, business acquisitions and new store openings, while profit declined substantially due to lower dispensing fees, higher costs and one-off M&A expenses. - FY2025-H1Higher revenue and a sharp decline in profit in the dispensing pharmacy businessAnnual report
「During the interim consolidated accounting period, the dispensing pharmacy business recorded revenue of ¥24,931 million, up 14.0% year on year, and segment profit of ¥202 million, down 75.6% year on year.」
Revenue increased due to higher prescription volumes resulting from M&A and new store openings, while segment profit fell 75.6% year on year due to the review of dispensing fees for chain groups with 300 or more stores, lower dispensing fees, and higher costs resulting from changes in procurement conditions. - FY2024Full-Year Revenue Growth and Profit DeclineAnnual report
「Revenue increased 4.4% year on year to ¥44,178 million. In terms of profit, however, the factors increasing profit, including higher prescriptions filled and expanded dispensing service fee revenue, were insufficient to offset the impact of the drug price revision, fluctuations in the purchasing environment, higher selling, general and administrative expenses associated with new store openings and M&A during the period, and higher taxes and public dues. Segment profit therefore declined 34.9% to ¥1,096 million.」
Revenue increased due to higher prescription volumes and dispensing service fee income, while profit declined due to drug price revisions, changes in procurement conditions, and higher costs related to new store openings and M&A. - FY2024-Q3Higher third-quarter revenue, lower profitAnnual report
「当第３四半期連結累計期間における調剤薬局事業の業績は、薬価改定の影響はあったものの、新型コロナウイルス感染症の影響による受診抑制の緩和や応需処方せん拡大の取り組み等を要因とした取扱処方せん枚数の増加を主因として、売上高は33,074百万円（前年同期比4.9％増）となりました。利益面においては、技術料の算定は順調に進展しているものの、当期に実施したＭ＆Ａや新規出店等による販管費の増加、仕入環境の変化及び薬価改定の影響を要因としてセグメント利益は1,036百万円（前年同期比8.2％減）となりました。」
Although the dispensing pharmacy business recorded higher revenue due to an increase in prescriptions filled and other factors, profit declined due to higher selling, general and administrative expenses associated with M&A and new store openings, changes in the purchasing environment and the impact of the drug price revision. - FY2024-Q2Second-Quarter Revenue and Profit GrowthAnnual report
「For the six-month period ended the second quarter, revenue in the dispensing pharmacy business increased 4.5% year on year to ¥21,876 million, and segment profit increased 11.6% to ¥831 million, due to M&A, the effects of new store openings, the recovery in prescriptions filled as restrictions on medical consultations eased following the impact of COVID-19, and increased dispensing service fees assessed.」
M&A, new store openings, the recovery in prescriptions filled and increased dispensing service fees assessed resulted in higher revenue and higher profit in the dispensing pharmacy business. - FY2024-Q1Higher revenue and lower profit in the first quarterAnnual report
「For the three-month period ended the first quarter, revenue in the dispensing pharmacy business increased 4.9% year on year to ¥10,898 million, due to the effects of M&A and new store openings, a clearer recovery trend in prescriptions filled from the second half of the previous fiscal year onward, mainly as restrictions on medical consultations eased following the impact of COVID-19, and increased dispensing service fees assessed. In terms of profit, however, the factors increasing profit, including higher prescriptions filled, higher average prescription values and expanded dispensing service fee revenue, were insufficient to offset the impact of changes in the purchasing environment. Segment profit therefore declined 4.6% to ¥379 million.」
Although M&A, new store openings, the recovery in prescriptions filled and increased dispensing service fees assessed contributed to higher revenue, the impact of changes in the purchasing environment could not be fully absorbed, resulting in lower profit in the dispensing pharmacy business. - FY2023Higher revenue and lower profit in the dispensing pharmacy businessAnnual report
「For the consolidated fiscal year, revenue in the dispensing pharmacy business increased 0.8% year on year to ¥42,327 million. In addition to the effects of M&A and new store openings, the recovery trend in prescriptions filled, driven mainly by the easing of restrictions on medical consultations following the impact of COVID-19, became more pronounced from the third quarter onward, and dispensing service fees assessed also increased. In terms of profit, however, the factors increasing profit, including the increase in prescriptions filled and expansion of dispensing service fee revenue, were insufficient to offset the impact of the drug price revision, changes in the purchasing environment and higher selling, general and administrative expenses associated with new store openings and M&A. Segment profit therefore declined 1.5% to ¥1,685 million.」
Although revenue increased due to higher prescriptions filled and dispensing service fee revenue, profit declined due to the drug price revision, changes in the purchasing environment and higher selling, general and administrative expenses associated with new store openings and M&A. - FY2023-Q3Higher revenue and lower profit in the dispensing pharmacy businessAnnual report
「当第３四半期連結累計期間における調剤薬局事業の業績は、新型コロナウイルス感染症の影響による受診抑制の緩和を背景とした処方せん枚数の回復の兆しや調剤技術料の算定増加等により売上高は31,532百万円（前年同期比0.4％増）と増収、利益面においては、薬価改定の影響及び仕入条件に係る見込差異の発生、当期に実施した新規出店やＭ＆Ａ等による販管費の増加等を主な要因としてセグメント利益は1,129百万円（前年同期比9.3％減）と減益になりました。」
Although revenue increased due to signs of a recovery in prescriptions filled and increased dispensing service fees assessed, profit declined due to the drug price revision, variances from estimates relating to purchasing terms and higher selling, general and administrative expenses associated with new store openings and M&A. - FY2023-Q2Lower revenue and lower profit in the dispensing pharmacy businessAnnual report
「For the six-month period ended the second quarter, revenue in the dispensing pharmacy business declined 0.3% year on year to ¥20,932 million due to the impact of the drug price revision. Although prescriptions filled showed signs of recovery as restrictions on medical consultations eased following the impact of COVID-19, and dispensing service fees assessed increased, segment profit declined 20.6% to ¥744 million. The main factors were unfavorable budget variances relating to purchasing terms and higher selling, general and administrative expenses due to new store openings and M&A carried out during the period.」
Although prescriptions filled showed signs of recovery and dispensing service fees assessed increased, the dispensing pharmacy business recorded lower revenue and lower profit due to unfavorable budget variances relating to purchasing terms and higher selling, general and administrative expenses associated with new store openings and M&A. - FY2023-Q1Lower revenue and higher profit in the dispensing pharmacy businessAnnual report
「For the three-month period ended the first quarter, revenue in the dispensing pharmacy business declined 1.2% year on year to ¥10,388 million due to the impact of the drug price revision. However, segment profit increased 5.4% to ¥398 million, mainly due to signs of a recovery in prescriptions filled as restrictions on medical consultations eased following the impact of COVID-19, as well as increased collection of dispensing service fees.」
Although revenue declined due to the drug price revision, profit increased as restrictions on medical consultations eased, prescriptions filled showed signs of recovery and the collection of dispensing service fees increased. - FY2022Lower revenue and higher profit in the dispensing pharmacy businessAnnual report
「Although revenue declined 1.2% year on year to ¥42,038 million due to the impact of the revenue recognition accounting standard, the drug price revision and other factors, segment profit increased 20.9% to ¥1,745 million. The main factors were signs of a recovery in prescriptions filled as restrictions on medical consultations eased following the impact of COVID-19, increased collection of dispensing service fees and the effect of expense reductions through control of selling, general and administrative expenses.」
The dispensing pharmacy business recorded lower revenue, while segment profit increased 20.9% due to signs of a recovery in prescriptions filled, increased collection of dispensing service fees and expense reductions. - FY2022-Q3Higher revenue and higher profit in the dispensing pharmacy businessAnnual report
「For the nine-month period ended the third quarter, revenue in the dispensing pharmacy business increased 0.7% year on year to ¥31,435 million, mainly due to a recovery from the decline in prescriptions filled caused by COVID-19. Segment profit increased 46.1% to ¥1,267 million.」
The dispensing pharmacy business recorded higher revenue due to the recovery from the decline in prescriptions filled and other factors, while segment profit also increased 46.1% year on year. - FY2022-Q2Higher revenue and higher profit in the dispensing pharmacy businessAnnual report
「For the six-month period ended the second quarter, revenue in the dispensing pharmacy business increased 1.5% year on year to ¥21,025 million, mainly due to a recovery from the decline in prescriptions filled caused by COVID-19. Segment profit increased 52.8% to ¥956 million.」
The dispensing pharmacy business recorded higher revenue due to the recovery from the decline in prescriptions filled and other factors, while segment profit also increased 52.8% year on year. - FY2022-Q1Higher revenue and a sharp increase in profit in the dispensing pharmacy businessAnnual report
「For the three-month period ended the first quarter, revenue in the dispensing pharmacy business increased 2.5% year on year to ¥10,586 million, mainly due to a recovery from the decline in prescriptions filled caused by COVID-19. Segment profit increased to ¥382 million from ¥27 million in the same period of the previous year.」
The dispensing pharmacy business recorded higher revenue due to the recovery from the decline in prescriptions filled and other factors, while segment profit increased from ¥27 million in the same period of the previous year to ¥382 million. - FY2021Higher revenue and higher profit in the dispensing pharmacy businessAnnual report
「Although the dispensing pharmacy business was affected by a decline in prescriptions filled resulting from the impact of COVID-19 and other factors, revenue increased 5.2% year on year to ¥42,530 million, partly due to the addition of a new operating company as a consolidated subsidiary. Segment profit also increased 9.1% to ¥1,444 million.」
The dispensing pharmacy business recorded higher revenue partly due to the contribution from a new consolidated subsidiary, while segment profit also increased 9.1% year on year. - FY2021-Q3Higher revenue and lower profit in the dispensing pharmacy businessAnnual report
「For the nine-month period ended the third quarter, revenue in the dispensing pharmacy business increased 2.2% year on year to ¥31,209 million, partly due to the addition of a new operating company as a consolidated subsidiary. However, segment profit declined 16.7% to ¥867 million, due mainly to the April 2020 drug price revision and a decline in prescriptions filled resulting from the impact of COVID-19.」
The business recorded higher revenue, partly due to the contribution from a new consolidated subsidiary, while segment profit declined 16.7% due to the drug price revision and the impact of COVID-19. - FY2021-Q2Continued higher revenue and a sharp decline in profit in the dispensing pharmacy businessAnnual report
「For the six-month period ended the second quarter, revenue in the dispensing pharmacy business increased 2.6% year on year to ¥20,712 million, partly due to the addition of a new operating company as a consolidated subsidiary. However, segment profit declined 29.1% to ¥625 million, due mainly to the April 2020 drug price revision and a decline in prescriptions filled resulting from the impact of COVID-19.」
The dispensing pharmacy business recorded higher revenue, partly due to the contribution from a new consolidated subsidiary, while segment profit declined 29.1% due to the drug price revision and the impact of COVID-19. - FY2021-Q1Higher revenue and a sharp decline in profit in the dispensing pharmacy businessAnnual report
「Despite these factors, as described above, the significant impact of COVID-19 and other factors resulted in higher revenue but lower profit in the dispensing pharmacy business for the three-month period ended the first quarter. Revenue was ¥10,325 million, up 1.1% year on year, while segment profit was ¥27 million, down 86.2%.」
The dispensing pharmacy business recorded higher revenue, while segment profit declined 86.2% year on year due mainly to the impact of COVID-19 and other factors. - FY2020AdvancedAnnual report
「As a result, for the consolidated fiscal year, the dispensing pharmacy business recorded revenue of ¥40,417 million, down 0.5% year on year, and segment profit of ¥1,323 million, up 40.0%.」
Despite a decline in prescriptions filled, segment profit in the dispensing pharmacy business increased 40.0% through the steady collection of dispensing service fees, control of cost of sales and control of selling, general and administrative expenses. - FY2020-Q3AdvancedAnnual report
「As a result, for the nine-month period ended the third quarter, the dispensing pharmacy business recorded revenue of ¥30,533 million, up 1.2% year on year, and segment profit of ¥1,041 million, up 98.6%.」
The dispensing pharmacy business recorded higher revenue, while segment profit increased 98.6% year on year to ¥1,041 million. The collection of dispensing service fees, control of cost of sales and expense reductions through control of selling, general and administrative expenses contributed to the overall improvement in profit. - FY2020-Q2AdvancedAnnual report
「As a result, for the six-month period ended the second quarter, the dispensing pharmacy business recorded revenue of ¥20,187 million, up 0.8% year on year, and segment profit of ¥882 million, up 164.6%.」
The dispensing pharmacy business recorded higher revenue, while segment profit increased 164.6% year on year to ¥882 million. Higher average prescription values, control of cost of sales and lower expenses were cited as factors behind the increase in profit. - FY2020-Q1AdvancedAnnual report
「In terms of profit, operating profit and ordinary profit both increased year on year, owing mainly to the steady collection of dispensing service fees in the dispensing pharmacy business.」
Supported by the steady collection of dispensing service fees and other factors in the dispensing pharmacy business, segment profit was ¥202 million, an increase of 269.7% year on year. - FY2018AdvancedAnnual report
「Total 3,790 3,986 100.0 105.2」
Prescriptions filled increased from 3,790 thousand to 3,986 thousand, reaching 105.2% of the level in the same period of the previous year. Dispensing service fees and other related revenue also increased from ¥9,056 million to ¥9,776 million. - FY2018-Q3First statedAnnual report
「In terms of profit, although the merchandise business remains on a path toward improved profitability, operating profit increased due to the steady number of prescriptions filled and the higher average prescription value resulting from the steady increase in dispensing service fees assessed.」
The company cited the steady number of prescriptions filled and the higher average prescription value resulting from increased dispensing service fees as factors behind the increase in operating profit.